Market Overview

10 Stocks Moving In Monday's Pre-Market Session

Share:


Gainers

Vascular Biogenics Ltd (NASDAQ: VBLT) shares rose 35.01 percent to $5.36 in pre-market trading following positive VB-111 data.

Exelixis, Inc. (NASDAQ: EXEL) rose 8.50 percent to $7.15 in pre-market trading. Exelixis and its partner Ipsen (OTC: IPSEY) reported positive positive overall survival results from subgroup analyses of Phase 3 trial of CABOMETYX tablets in advanced renal cell carcinoma.

Xcerra Corp (NASDAQ: XCRA) shares rose 6.57 percent to $7.46 in pre-market trading. Xcerra reported Q3 earnings of $0.00 per share on revenue of $82.237 million.

Eleven Biotherapeutics Inc (NASDAQ: EBIO) shares rose 6.05 percent to $2.28 in pre-market trading after surging 20.79 percent on Friday.

Array Biopharma Inc (NASDAQ: ARRY) rose 3.43 percent to $3.92 in pre-market trading. Array BioPharma, Pierre Fabre and Merck KGaA reported Phase 3 BEACON CRC trial.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Losers

ProNAi Therapeutics Inc (NASDAQ: DNAI) shares 60.82 percent to $2.50 in pre-market trading after the company reports interim data from Wolverine Phase 2 trial of PNT2258 in diffuse large B-cell lymphoma (DLBCL). The company discontinued the development of DLBCL.

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) fell 45.94 percent to $4.79 in pre-market trading as the company revealed Monday it was advised by the FDA to expand its human study, as well as reliability student, i.e. product stress testing, to get its support for its NDA for Epinephrine injection. The medical regulator issued a complete response letter to it on Friday after the market closed.

Ocular Therapeutix Inc (NASDAQ: OCUL) shares fell 32.49 percent to $8.00 in pre-market trading after the company reported Phase 3 clinical trial of DEXTENZA for allergic conjunctivitis. The trail did not meet primary endpoint.

Lion Biotechnologies Inc (NASDAQ: LBIO) shares fell 5.43 percent to $8.18 in pre-market trading after surging 43.45 percent on Friday.

AbbVie Inc (NYSE: ABBV) shares fell 3.68 percent to $62.64. AbbVie presented Phase 1 data for ABT-414. Cowen & Company downgraded AbbVie from Outperform to Market Perform.

 

Related Articles (EXEL + VBLT)

View Comments and Join the Discussion!

Posted-In: #PreMarket Gainers LosersNews Movers & Shakers Pre-Market Outlook Markets Movers